Alteraciones del metabolismo fosfocálcico. Hipercalcemia. Hiperparatiroidismo

  1. A. Muñoz Garach 2
  2. A. García Martín 1
  3. M. Muñoz Torres 1
  1. 1 UGC Endocrinología y Nutrición. Complejo Hospitalario Universitario de Granada. Granada. España
  2. 2 UGC Endocrinología y Nutrición. Hospital Universitario Virgen de la Victoria. Málaga. España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2016

Issue Title: Enfermedades endocrinológicas y metabólicas (IV) Patología del metabolismo fosfocálcico

Series: 12

Issue: 16

Pages: 893-899

Type: Article

DOI: 10.1016/J.MED.2016.07.002 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Introduction Hypercalcaemia is a relatively common disorder. Ninety percent of hypercalcaemia cases take place in the context of primary hyperparathyroidism (PHP) and tumour-induced hypercalcaemia. Symptoms A considerable variety of symptoms affecting several organs and systems have been described, including the specific manifestations of PHP (nephrolithiasis and osteitis fibrosa cystica), although the most common manifestation is asymptomatic PHP. Diagnosis The first test to request for the aetiological diagnosis of hypercalcaemia should be the parathyroid hormone (PTH) measurement, followed by the measurement of phosphorus, vitamin D and 24-h urine levels to determine calciuria and creatinine clearance. Treatment The most important measure in treating severe hypercalcaemia is rehydration, followed by treatment with intravenous zoledronate to subsequently resolve the underlying cause. For PHP, the only curative treatment is parathyroidectomy.

Bibliographic References

  • Longo DL, Kasper DL, Lameson JL, Fauci AS, Hauser SL, Loscalzo J, editores. Harrison. Principios de Medicina Interna. 18ª ed. Madrid: Ed. McGraw-Hill; 2012.
  • Rozman C, Cardellach F, editores. Farreras-Rozman. Medicina Interna. 17ª ed. Barcelona: Elsevier;
  • Rosen CJ, editor; American Society for Bonoe and Mineral Research. Primer on the metabolic bone diseases and disorders of mineral metabo-lism. 8th ed. Washington Wiley-Blackwell; 2013.
  • Bringhurst FR, Demay MB, Kronenberg HM. Hormonas y alteraciones del metabolismo mineral. En: Melmed S, Polonsky K, Larsen PR, Kronenberg HM editores. Williams textbook of endo-crinology. 12ª ed. EEUU: Saunders Elsevier; 2011. p. 1246-53.
  • Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3561-9.
  • Endres DB. Investigation of hypercalcemia. Clin Biochem. 2012;45:954-63.
  • Shane E. Etiology of hypercalcemia. Disponible en: www.uptodate.com
  • Christie CR, Achenie LE, Ogunnaike BA. A control engineering model of calcium regulation. J Clin Endocrinol Metab. 2014;99:2844-53.
  • Christensen SE, Nissen PH, Vestergaard P, Mosekilde L. Familial hypo-calciuric hypercalcemia: a review. Curr Opin Endocrinol Diabetes Obes. 2011;18:359-70.
  • Maier JD, Levine SN. Hypercalcemia in the intensive care unit: A review of pathophysiology, diagnosis, and modern therapy. J Intensive Care Med. 2015;30:235-52.
  • Clines GA. Mechanism and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes. 2011;18:339-46.
Data source: Dialnet